NSE filing, NSE: ACCPL. Summary written from the filing by ALFA Finder's alert engine.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹181.00
- Market cap
- ₹201.2 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 20.8×Sector 46.1×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited announced the results of its postal ballot, where shareholders approved five special resolutions, including increasing borrowing limits and charging company assets.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited held its 3rd Annual General Meeting on August 27, 2026. The meeting transacted business including the adoption of financial statements and director re-appointment.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited has provided the web link for shareholders to access its Annual Report for FY 2025-26 and the 3rd AGM notice.
Other other announcement announcements
All →Milky Mist Dairy Food Other Announcement
Milky Mist's board appointed B Chandra & Associates as Secretarial Auditors for FY 2026-27 to 2030-31. Shareholder approval is pending at the ensuing AGM.
- Execution
- FY 2026-27 to FY 2030-31 (five years)
Mahamaya Lifesciences Other Announcement
Mahamaya Lifesciences Ltd, an SME-platform listed company, confirms non-applicability of Corporate Governance under Regulation 27(2) for the quarter ended 30 September 2026. A Company Secretary certificate is enclosed.
Wipro Other Announcement
Wipro disclosed a designated person's 34,200-share ADR sale worth about ₹0.67 Crore on 28 October 2026. The sale followed RSU exercise, leaving 60,266 securities held.
- Value
- ₹0.67 Cr
OK Play India Other Announcement
OK Play India filed its quarterly shareholding pattern for the quarter ended September 2026. It shows category holdings only, with no transaction.
Spice Islands Industries Other Announcement
Spice Islands Industries filed a Reg 32 statement reporting no deviation in preferential issue fund utilization for Q3 FY27. The ₹8.70 Crore raise is fully deployed.
Setubandhan Infrastructure Other Announcement
RP informs exchanges that Setubandhan Infrastructure cannot file quarterly compliance documents due to depository fee non-payment. The company remains under CIRP with a pending NCLAT appeal.